Sana Biotechnology, Inc. (SANA) Stock Forecast
SANA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.56 / 5 from 9 analysts
- Price target
- $8.43 average of analyst targets
- Upside to target
- +271.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.18
- 52-week range
- $2.27 – $5.71
SANA analyst ratings
9 analystsNumber of analysts at each rating.
SANA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SANA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.19 | −$0.10 | −$0.15 | +11.0% | 4 |
| Current fiscal year (2026) | −$0.59 | −$0.71 | −$0.48 | −$0.67 | +11.8% | 4 |
| Next fiscal year (2027) | −$0.56 | −$0.74 | −$0.42 | −$0.59 | +6.1% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SANA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 6 |
SANA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SANA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.12 | −$0.12 | −$0.12 | −$0.13 | +8.3% | 2 up · 1 down |
| Current fiscal year (2026) | −$0.60 | −$0.60 | −$0.58 | −$0.58 | −$0.59 | −0.7% | 2 up · 2 down |
| Next fiscal year (2027) | −$0.54 | −$0.54 | −$0.52 | −$0.52 | −$0.56 | +3.1% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SANA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SANA beat in 8 of 12.
What analysts expect from SANA
9 analysts cover Sana Biotechnology; their consensus rating is strong buy (4.56 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.43, 271.3% above the latest close of $2.27. Analysts expect earnings of −$0.59 per share for 2026, +11.8% from a year earlier. For 2027 the average estimate is −$0.56 per share. Sana Biotechnology beat the EPS estimate in 8 of the last 12 quarters.
Related: SANA income statement, SANA key metrics, SANA chart. See the SANA stock overview for the latest quote and news.
SANA forecast FAQ
What is Sana Biotechnology's price target?
The average analyst price target for Sana Biotechnology is $8.43, 271.3% above the latest close of $2.27.
Is Sana Biotechnology a buy, hold or sell?
Of 9 analysts covering Sana Biotechnology, 6 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Sana Biotechnology's EPS forecast?
Analysts forecast −$0.59 per share for 2026 (range −$0.71 to −$0.48); for 2027 the estimate is −$0.56.
When does Sana Biotechnology report earnings?
Sana Biotechnology is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.18.
Does Sana Biotechnology usually beat earnings estimates?
Sana Biotechnology reported EPS at or above the analyst estimate in 8 of the last 12 quarters.